Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool

American Journal of Pathology

Volumn 166, Issue 4, 2005, Pages 1041-1053

  Davies, Reginald ^a   Schuurman, Arenda ^a   Barker, Colin R ^a   Clothier, Bruce ^a   Chernova, Tatyana ^a   Higginson, Fiona M ^a   Judah, David J ^a   Dinsdale, David ^a   Edwards, Richard E ^a   Greaves, Peter ^a   Gant, Timothy W ^a   Smith, Andrew G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; BENZENE DERIVATIVE; CARRIER PROTEIN; CYTOCHROME P450; FERROCHELATASE; HEME;

ALAS1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT INJURY; CHOLESTASIS; CONTROLLED STUDY; ERYTHROPOIETIC PROTOPORPHYRIA; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEME SYNTHESIS; HMOX1 GENE; LIVER METABOLISM; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 20244387842     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62325-5     Document Type: Article

References (57)

1. Dailey HA, Dailey TA: Ferrochelatase. The Porphyrin Handbook. Edited by Kadish KM, Smith KM, Guilard RG. Amsterdam, Elsevier, 2003, pp 93-121
2. Anderson KE, Sassa S, Bishop DF, Desnick RJ: Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The Metabolic and Molecular Basis of Inherited Disease. Edited by Scriver CR, Beudet AL, Sly WS, Valle D, Vogelstein B, Childs MD. New York, McGraw-Hill, 2001, pp 2991-3062
3. Beukeveld GJ, In't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F: Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J Hepatol 1996, 24:343-352
4. Meerman L: Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J Gastroenterol 2000, 35(Suppl 232):79-85
5. Cox TM: Protoporphyria. The Porphyrin Handbook. Edited by Kadish KM, Smith KM, Guilard RG. Amsterdam, Elsevier, 2003, pp 121-149
6. Bloomer JR, Poh-Fitzpatrick MB: Theodore Woodward Award. Pathogenesis of biochemical abnormalities in protoporphyria. Trans Am Clin Climatol Assoc 2000, 111:245-256
7. Ishibashi A, Ogata R, Sakisaka S, Kumashiro R, Koga Y, Mitsuyama K, Kuromatsu R, Uchimura Y, Ijyuin H, Tanaka K, Iwao T, Ishii K, Sata M, Inoue Y, Kin Y, Oizumi K, Nishida H, Imaizumi T, Tanikawa K: Erythropoietic protoporphyria with fatal liver failure. J Gastroenterol 1999, 34:405-409
8. Meerman L, Haagsma EB, Gouw AS, Slooff MJ, Jansen PL: Long-term follow-up after liver transplantation for erythropoietic protoporphyria. Eur J Gastroenterol Hepatol 1999, 11:431-438
9. Tutois S, Montagutelli X, Da Silva V, Jouault H, Rouyer-Fessard P, Leroy-Viard K, Guenet JL, Nordmann Y, Beuzard Y, Deybach JC: Erythropoietic protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. J Clin Invest 1991, 88:1730-1736
10. Boulechfar S, Lamoril J, Montagutelli X, Guenet JL, Deybach JC, Nordmann Y, Dailey H, Grandchamp B, de Verneuil H: Ferrochelatase structural mutant (Fechm1Pas) in the house mouse. Genomics 1993, 16:645-648
11. Pawliuk R, Bachelot T, Wise RJ, Mathews-Roth MM, Leboulch P: Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999, 5:768-773
12. Fontanellas A, Mazurier F, Landry M, Taine L, Morel C, Larou M, Daniel JY, Montagutelli X, de Salamanca RE, de Verneuil H: Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria. Hepatology 2000, 32:73-81
13. Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG, Kramer W, Stengelin S, Muller M, Kuipers F, Jansen PL: Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 1999, 117:696-705
14. Bloks VW, Plosch T, van Goor H, Roelofsen H, Baller J, Havinga R, Verkade HJ, van Tol A, Jansen PL, Kuipers F: Hyperlipidemia and atherosclerosis associated with liver disease in ferrochelatase-deficient mice. J Lipid Res 2001, 42:41-50
15. Libbrecht L, Meerman L, Kuipers F, Roskams T, Desmet V, Jansen P: Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 2003, 199:191-200
16. De Matteis F, Marks GS: Cytochrome P450 and its interactions with the heme biosynthetic pathway. Can J Physiol Pharmacol 1996, 74:1-8
17. Gant TW, Baus PR, Clothier B, Riley J, Davies R, Judah DJ, Edwards RE, George E, Greaves P, Smith AG: Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin. Environ Health Perspect 2003, 111:847-853
18. Smith AG, Carthew P, Francis JE, Edwards RE, Dinsdale D: Characterization and accumulation of ferritin in hepatocyte nuclei of mice with iron overload. Hepatology 1990, 12:1399-1405
19. Grandchamp B, Deybach JC, Grelier M, de Verneuil H, Nordmann Y: Studies of porphyrin synthesis in fibroblasts of patients with congenital erythropoietic porphyria and one patient with homozygous coproporphyria. Biochim Biophys Acta 1980, 629:577-586
20. Smith AG, Clothier B, Carthew P, Childs NL, Sinclair PR, Nebert DW, Dalton TP: Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2001, 173:89-98
21. Omura T, Sato R: The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 1964, 239:2379-2385
22. Jover R, Hoffmann F, Scheffler-Koch V, Lindberg RL: Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital. Eur J Biochem 2000, 267:7128-7137
23. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, Smith AG, Gant TW: Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 2001, 20:1300-1306
24. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, Nebert DW: Intrinsic hepatic phenotype associated with the cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. Environ Health Perspect 2003, 111:855-861
25. Zhang S-D, Gant TW: A statistical framework for the design of microarray experiments and effective detection of differential gene expression. Bioinformatics 2004, 20:2821-2828
26. Hamilton JW, Bement WJ, Sinclair PR, Sinclair JF, Alcedo JA, Wetterhahn KE: Heme regulates hepatic 5-aminolevulinate synthase mRNA expression by decreasing mRNA half-life and not by altering its rate of transcription. Arch Biochem Biophys 1991, 289:387-392
27. Cable EE, Miller TG, Isom HC: Regulation of heme metabolism in rat hepatocytes and hepatocyte cell lines: delta-aminolevulinic acid synthase and heme oxygenase are regulated by different heme-dependent mechanisms. Arch Biochem Biophys 2000, 384:280-295
28. Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, Repa JJ: Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA 2003, 100:223-228
29. Li-Hawkins J, Lund EG, Turley SD, Russell DW: Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J Biol Chem 2000, 275:16536-16542
30. Trauner M, Boyer JL: Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003, 83:633-671
31. Jung D, Kullak-Ublick GA: Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003, 37:622-631
32. Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71:537-592
33. Camus-Randon AM, Raffalli F, Bereziat JC, McGregor D, Konstandi M, Lang MA: Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol Appl Pharmacol 1996, 138:140-148
34. Kobliakov V, Kulikova L, Samoilov D, Lang MA: High expression of cytochrome P450 2a-5 (coumarin 7-hydroxylase) in mouse hepatomas. Mol Carcinog 1993, 7:276-280
35. Salonpaa P, Krause K, Pelkonen O, Raunio H: Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn Schmiedebergs Arch Pharmacol 1995, 351:446-452
36. Kakizaki S, Yamamoto Y, Ueda A, Moore R, Sueyoshi T, Negishi M: Phenobarbital induction of drug/steroid-metabolizing enzymes and nuclear receptor CAR. Biochim Biophys Acta 2003, 1619:239-242
37. Fraser DJ, Zumsteg A, Meyer UA: Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J Biol Chem 2003, 278:39392-39401
38. Inafuku K, Takamiyagi A, Oshiro M, Kinjo T, Nakashima Y, Nonaka S: Alteration of mRNA levels of delta-aminolevulinic acid synthase, ferrochelatase and heme oxygenase-1 in griseofulvin induced protoporphyria mice. J Dermatol Sci 1999, 19:189-198
39. Knobler E, Poh-Fitzpatrick MB, Kravetz D, Vincent WR, Muller-Eberhard U, Vincent SH: Interaction of hemopexin, albumin and liver fatty acid-binding protein with protoporphyrin. Hepatology 1989, 10:995-997
40. Vincent SH, Smith AG, Muller-Eberhard U: Modulation of hepatic heme-binding Z protein in mice by the porphyrogenic carcinogens griseofulvin and hexachlorobenzene. Cancer Lett 1989, 45:109-114
41. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002, 99:15649-15654
42. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, Muller M: Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 1998, 28:1637-1644
43. Schrenk D, Gant TW, Preisegger KH, Silverman JA, Marino PA, Thorgeirsson SS: Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 1993, 17:854-860
44. Buchberg AM, Kinniburgh AJ: Induction of liver apolipoprotein A-IV mRNA in porphyric mice. Nucleic Acids Res 1985, 13:1953-1963
45. Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, Weslie Tyson R, Sokol RJ, Russell DW: Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998, 102:1690-1703
46. Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, Dietschy JM, Turley SD: Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J Biol Chem 2000, 275:39685-39692
47. Setchell KD, Rodrigues CM, Clerici C, Solinas A, Morelli A, Gartung C, Boyer J: Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997, 112:226-235
48. Stedman C, Robertson G, Coulter S, Liddle C: Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J Biol Chem 2004, 279:11336-11343
49. Dalton TP, Shertzer HG, Puga A: Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999, 39:67-101
50. Tolosano E, Fagoonee S, Hirsch E, Berger FG, Baumann H, Silengo L, Altruda F: Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 2002, 100:4201-4208
51. Bataller R, North KE, Brenner DA: Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003, 37:493-503
52. Brodie MJ, Moore MR, Thompson GG, Campbell BC, Goldberg A: Is porphobilinogen deaminase activity a secondary control mechanism in heme biosynthesis in humans? Biochem Soc Trans 1977, 5:1466-1468
53. Sassa S, Nagai T: The role of heme in gene expression. Int J Hematol 1996, 63:167-178
54. De Matteis F, Gibbs AH: Stimulation of the pathway of porphyrin synthesis in the liver of rats and mice by griseofulvin, 3,5-diethoxycarbonyl-1,4- dihydrocollidine and related drugs: evidence for two basically different mechanisms. Biochem J 1975, 146:285-287
55. Holley A, King LJ, Gibbs AH, De Matteis F: Strain and sex differences in the response of mice to drugs that induce protoporphyria: role of porphyrin biosynthesis and removal. J Biochem Toxicol 1990, 5:175-182
56. Denk H, Eckerstorfer R: Turnover of cytochrome P-450 and cytochrome b5 hemes in griseofulvin-induced murine porphyria. FEBS Lett 1977, 76:67-70
57. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, psuedogenes and alternative-splice variants. Pharmacogenetics 2004, 14:1-18